Menu Search
Equities

Lokaty Budowlane SA

LBD:WSE

Lokaty Budowlane SA

Actions
  • Price (PLN)0.51
  • Today's Change0.04 / 8.51%
  • Shares traded217.00
  • 1 Year change+3.24%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lokaty Budowlane SA, formerly Fabryka Diet SA, is a Poland-based company active within the real estate sector. The Company is engaged in the homebuilding and construction of commercial buildings. Among its realizations are Conference Centre Hotel Swiecice and single-family houses in Ozarow Mazowiecki. The Company was established as a result of a merger by incorporation between Fabryka Diet SA and Osiedle Poniatowskie Sp z o o. On July 10, 2014, the Company established new subsidiary Medycyna Estetyczna DR Ertuganow Sp z o o, providing healthcare and rehabilitation services.

  • Revenue in -- (TTM)--
  • Net income in --
  • Incorporated2008
  • Employees--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.